Since NK cells also express natural cytotoxicity receptors (NCRs) that recognize ligands on tumor targets and mediate activating signals, modification of NK cells with engineered NCR transgenes in combination with either modified NKG2D or enhanced CD16 receptors may lead to a more robust NK cell therapy and improve anti-tumor activity. The gene discussed is KLRK1; the disease is neoplasm.